南宫NG28基因
About Us
Corporate Profile
Management Team
Milestones
Awards
Our Vision
Affiliates
CTTQ Akesobio
Akeso Pharma
AD Pharmaceuticals
Contact Us
R&D and science
Technology Platform
Pipelines
Products Center
R&D and Manufacturing
Expanded Access Policy
Collaborations
Investor Relations
Financial Reports
Presentations
IR Monthly Reports
Announcements and Circulars
Corporate Governance
IR Calendar
IR Contact
Media
Career
Now Hiring
简
|
EN
|
Akeso News
Monthly News
2024-09-08
WCLC 2024 | Akeso's Ivonescimab Head-to-Head Phase III Data Against Pembrolizumab Unveiled
2024-09-06
Akeso to Present Data from 13 Clinical Studies at ESMO 2024, Featuring its Internally Developed Cadonilimab, Ivonescimab, Ligufalimab, and other I/O Antibodies
2024-08-29
Akeso's 2024 First Half Interim Results: Expanding Global Lead in IO Bispecific Antibodies, Advancing New Therapies, and Accelerating Commercialization
2024-08-15
Ivonescimab (PD-1/VEGF) Received Priority Review from China’s NMPA for First-Line Treatment of PD-L1 Positive NSCLC
2024-08-10
Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024
2024-08-06
First Patient Enrolled in the US Phase 2 Combination Therapy of Akeso's Ligufalimab with Azacitidine for Myelodysplastic Syndrome
2024-07-29
Akeso's sNDA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA
2024-05-31
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
2024-05-30
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC
2024-04-08
Oral report | The positive interim analysis results from the Phase III clinical study of Akeso's Cadonilimab (PD-1/CTLA-4 BsAb) plus chemotherapy as first-line treatment for advanced gastric cancer presented at 2024 AACR
2024-03-06
Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-line Treatment of PD-L1 negative NSCLC
2024-02-28
The promising results of a phase II clinical study for Akeso's Cadonilimab (PD-1/CTLA-4) combined standard treatment for first-line treatment of R/M cervical cancer has been published in Clinical Cancer Research
«
1
2
3
4
5
6
7
8
9
»
